16.86
price up icon5.57%   0.89
after-market アフターアワーズ: 17.26 0.40 +2.37%
loading
前日終値:
$15.97
開ける:
$15.76
24時間の取引高:
208.88K
Relative Volume:
1.77
時価総額:
$147.60M
収益:
$123.24M
当期純損益:
$136.00K
株価収益率:
-843.00
EPS:
-0.02
ネットキャッシュフロー:
$-148.99M
1週間 パフォーマンス:
+10.27%
1か月 パフォーマンス:
+13.54%
6か月 パフォーマンス:
+1.24%
1年 パフォーマンス:
-6.65%
1日の値動き範囲:
Value
$15.76
$17.52
1週間の範囲:
Value
$14.06
$17.52
52週間の値動き範囲:
Value
$6.53
$26.40

Seres Therapeutics Inc Stock (MCRB) Company Profile

Name
名前
Seres Therapeutics Inc
Name
セクター
Healthcare (1156)
Name
電話
617 945 9626
Name
住所
200 SIDNEY STREET, CAMBRIDGE, MA
Name
職員
103
Name
Twitter
@SeresTX
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
MCRB's Discussions on Twitter

MCRB を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
MCRB
Seres Therapeutics Inc
16.86 139.81M 123.24M 136.00K -148.99M -0.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
390.30 101.51B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
565.97 59.52B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
442.73 56.69B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
652.43 39.57B 3.06B 1.28B -614.78M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
309.69 36.56B 3.81B -644.79M -669.77M -6.24

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-08 ダウングレード Chardan Capital Markets Buy → Neutral
2024-10-24 ダウングレード JP Morgan Neutral → Underweight
2023-06-26 再開されました Oppenheimer Outperform
2023-04-21 開始されました JP Morgan Neutral
2021-07-23 ダウングレード Goldman Neutral → Sell
2021-05-18 再開されました Goldman Neutral
2021-03-05 アップグレード Chardan Capital Markets Neutral → Buy
2020-09-18 ダウングレード Chardan Capital Markets Buy → Neutral
2020-08-18 開始されました Piper Sandler Overweight
2020-08-11 繰り返されました H.C. Wainwright Buy
2020-08-11 アップグレード Jefferies Hold → Buy
2019-04-30 開始されました Jefferies Hold
2018-10-22 開始されました Chardan Capital Markets Buy
2017-10-13 開始されました Oppenheimer Outperform
2017-08-04 繰り返されました H.C. Wainwright Buy
2017-02-01 繰り返されました FBR & Co. Outperform
2016-08-12 繰り返されました FBR Capital Outperform
2016-08-01 ダウングレード BofA/Merrill Buy → Neutral
2016-08-01 繰り返されました H.C. Wainwright Buy
2016-07-29 再開されました H.C. Wainwright Buy
2016-03-30 開始されました FBR Capital Outperform
2016-03-03 開始されました Guggenheim Buy
2016-01-25 開始されました H.C. Wainwright Buy
2015-10-22 アップグレード BofA/Merrill Neutral → Buy
2015-07-22 開始されました Canaccord Genuity Buy
2015-07-21 開始されました Goldman Neutral
2015-07-21 開始されました Leerink Partners Outperform
すべてを表示

Seres Therapeutics Inc (MCRB) 最新ニュース

pulisher
Aug 10, 2025

Seres Therapeutics Inc. Bounces Off Moving Average SupportReal Trader Watchlist of Hot Stocks Released - metal.it

Aug 10, 2025
pulisher
Aug 09, 2025

Seres (MCRB) Q2 Loss Narrows 34% - AOL.com

Aug 09, 2025
pulisher
Aug 08, 2025

Seres Therapeutics Reports Q2 2025 Financial Results - The Globe and Mail

Aug 08, 2025
pulisher
Aug 07, 2025

Seres Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Seres Therapeutics shares fall 1.90% after-hours following Q2 2025 earnings call. - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Promising Developments and Strategic Partnerships Drive Buy Rating for Seres Therapeutics - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Seres Therapeutics outlines global Phase II SER-155 trial with 248-patient enrollment amid partnership talks - MSN

Aug 07, 2025
pulisher
Aug 07, 2025

Seres Therapeutics: Q2 Earnings Snapshot - Connecticut Post

Aug 07, 2025
pulisher
Aug 06, 2025

Seres Therapeutics: Unpacking Strategic Contradictions in Partnerships and FDA Engagements - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

Seres Therapeutics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:MCRB) - Seeking Alpha

Aug 06, 2025
pulisher
Aug 06, 2025

Transcript : Seres Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener

Aug 06, 2025
pulisher
Aug 06, 2025

Sana Biotechnology shares fall 14.12% after-hours following Seres Therapeutics' board changes and clinical advancement updates. - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

Seres Therapeutics, Inc. SEC 10-Q Report - TradingView

Aug 06, 2025
pulisher
Aug 06, 2025

Earnings call transcript: Seres Therapeutics reports larger-than-expected Q2 loss - Investing.com Canada

Aug 06, 2025
pulisher
Aug 06, 2025

Seres Therapeutics quarterly loss per share $2.27 - MarketScreener

Aug 06, 2025
pulisher
Aug 06, 2025

Seres Therapeutics August 2025 slides: SER-155 shows 77% infection reduction - Investing.com

Aug 06, 2025
pulisher
Aug 06, 2025

Nxera debuts an obesity pipeline; BridgeBio battles Alynam for market share - Yahoo Finance

Aug 06, 2025
pulisher
Aug 06, 2025

Seres Therapeutics: A High-Conviction Biotech Buy Amid Clinical and Strategic Momentum - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

Seres Therapeutics Reports Second Quarter 2025 Financial Results - GuruFocus

Aug 06, 2025
pulisher
Aug 06, 2025

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance

Aug 06, 2025
pulisher
Aug 04, 2025

Seres Therapeutics Inc. Stock Analysis and ForecastAchieve consistent profits with proven methods - Jammu Links News

Aug 04, 2025
pulisher
Aug 03, 2025

Is Seres Therapeutics Inc. a growth stock or a value stockRapid portfolio appreciation - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Seres Therapeutics Inc. a good long term investmentAchieve breakthrough gains with smart trades - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does Seres Therapeutics Inc. compare to its industry peersMaximize your portfolio’s growth potential - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are Seres Therapeutics Inc. company’s key revenue driversConsistent high-yield stocks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

When is Seres Therapeutics Inc. stock expected to show significant growthInvest confidently with real-time data - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are analysts’ price targets for Seres Therapeutics Inc. in the next 12 monthsBuild a diversified portfolio for maximum returns - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Should I hold or sell Seres Therapeutics Inc. stock in 2025Build a portfolio that grows with the market - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

What analysts say about Seres Therapeutics Inc. stockUnmatched profit potential - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What makes Seres Therapeutics Inc. stock price move sharplyBuild wealth with steady, reliable stocks - Jammu Links News

Aug 02, 2025
pulisher
Aug 01, 2025

Why is Seres Therapeutics Inc. stock attracting strong analyst attentionRetirement Planning Entry Points For Consistent Profits - Jammu Links News

Aug 01, 2025
pulisher
Jul 29, 2025

Is Seres Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis Inside - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Seres Therapeutics: Speculative Gem with FDA Breakthrough Potential - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough - Seeking Alpha

Jul 29, 2025
pulisher
Jul 29, 2025

Why Seres Therapeutics Inc. stock attracts strong analyst attentionEntry Zone Strategy for Consistent Profit Shared - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

What institutional investors are buying Seres Therapeutics Inc. stockPhenomenal wealth increase - Jammu Links News

Jul 28, 2025
pulisher
Jul 28, 2025

How many analysts rate Seres Therapeutics Inc. as a “Buy”Build wealth with reliable stock picks - Jammu Links News

Jul 28, 2025
pulisher
Jul 28, 2025

Will Seres Therapeutics Inc. Recover After Recent DeclineStock Market Entry Timing Signals Revealed - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

What is the dividend policy of Seres Therapeutics Inc. stockSkyrocketing returns - Jammu Links News

Jul 28, 2025

Seres Therapeutics Inc (MCRB) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$36.50
price up icon 0.11%
$86.16
price up icon 0.36%
$26.45
price down icon 1.56%
$127.75
price up icon 3.97%
$112.70
price down icon 0.07%
biotechnology ONC
$309.69
price up icon 0.71%
大文字化:     |  ボリューム (24 時間):